Stocks are crashing and soaring ahead of scheduled U.S. Food and Drug Administration (FDA) drug approvals in Q3 - Q4 2013. Twelve promising compounds remain on the FDA drug approval calendar in August - December of this year. If approved, the drugs can finally reach the market and begin to generate revenue for their developers, who have likely spent millions on the drug's development.
Many of the drugs' stocks are on the increase running up to the FDA verdict date, but many drugs warrant low investor confidence following poor clinical trial performance or negative FDA Advisory Committee (AdCom) meetings.
Familiarity with the FDA regulatory landscape can yield great insight into event-triggered stock investing. Check out Bioassociate's latest report: FDA Stock Catalysts: Drug Approvals August - December 2013 for novel regulatory changes and for a breakdown of very interesting compounds still awaiting approval this year.